Transdermal cannabidiol gel (ZYN002) in Fragile X syndrome: phase 3 RCT (CONNECT-FX)

Introduction and clinical context

The study Transdermal cannabidiol gel (ZYN002) in Fragile X syndrome: phase 3 RCT (CONNECT-FX) (J Neurodevelop Disord · 2022) is part of the scientific research on the use of cannabinoids in rare syndromes.

In rare genetic syndromes associated with epilepsy and neurodevelopmental disorders — such as Fragile X syndrome and CDKL5 —, cannabidiol is investigated for seizures and behavioral symptoms. Phase 3 trials (such as CONNECT-FX, with transdermal CBD gel) and open-label studies report benefit in specific subgroups. These are complex conditions, and treatment is highly individualized and specialized.

Understanding what science shows about the use of cannabinoids in rare syndromes helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Phase 3 RCT (212 children/adolescents): significant behavioral improvement in the subgroup with ≥90% FMR1 methylation. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In rare genetic syndromes with epilepsy, cannabidiol acts through anticonvulsant mechanisms largely independent of the classic CB1/CB2 receptors, modulating neuronal excitability — the basis for the seizure reduction observed in subgroups. Safety includes drowsiness, appetite changes and a possible rise in liver enzymes, with monitoring, in addition to the relevant interaction with clobazam. As these involve children with complex conditions, titration is gradual and the follow-up specialized. Treatment is highly individualized, weighing the benefit in seizure reduction and tolerability.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (J Neurodevelop Disord · 2022). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does CBD help in rare syndromes?

Trials and open-label studies report benefit in subgroups; treatment is highly individualized.

What is CONNECT-FX?

A phase 3 trial with transdermal CBD gel (ZYN002) in Fragile X syndrome.